Pre-mercato: 124.88 -0.01 -0.01%

Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

Dimensional Fund Advisors LP Has $40.35 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Insider Monkey

Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts? - Yahoo Finance

Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher - sharewise

Sarepta Therapeutics' SWOT analysis: broad elevidys label boosts stock outlook - Investing.com

7 Best Revenue Growth Stocks to Buy According to Analysts - Insider Monkey

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - BioSpace

Dispute over Duchenne gene therapy highlights thorny access issues - STAT

Lighthouse Investment Partners LLC Invests $7.95 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

The Play On Sarepta Therapeutics (NASDAQ:SRPT) - Seeking Alpha

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress - StockTitan

Duchenne Muscular Dystrophy Treatment Market Will Accelerate - openPR

Point72 Hong Kong Ltd Acquires New Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Fred Alger Management LLC - MarketBeat

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Avoro Capital Advisors LLC - MarketBeat

Exploring TeraWulf And Two Other High Growth Tech Stocks - Simply Wall St

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Profund Advisors LLC Buys 17,132 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Ensign Peak Advisors Inc - Defense World

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - MSN

Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity - Yahoo Finance

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Forecasted to Post Q1 2026 Earnings of $2.75 Per Share - MarketBeat

Sarepta Therapeutics (NASDAQ:SRPT) Receives Neutral Rating from Cantor Fitzgerald - MarketBeat

Zacks Research Equities Analysts Boost Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Simplify Asset Management Inc. - MarketBeat

Sarepta Therapeutics (NASDAQ:SRPT) Receives "Outperform" Rating from Royal Bank of Canada - MarketBeat

Marvell co-founder Sehat Sutardja has died as industry mourns semiconductor visionary - DIGITIMES

Blair William & Co. IL Has $27.54 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Sehat Sutardja, semiconductor pioneer and Marvell co-founder, has died - Berkeley Engineering

Sacha Feinberg-Mngomezulu is the future of the Springboks, but don’t write off Manie Libbok just yet - IOL

Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options - Yahoo Finance

Blair William & Co. IL Increases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

16 Best Mid Cap Growth Stocks To Buy Now - Insider Monkey

Sarepta Therapeutics Muscles Up In DMD Race - Seeking Alpha

Rassie unhappy with Sacha after ‘hiding’ injury - MSN

Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $188.00 at UBS Group - MarketBeat

Sofinnova Investments Inc. Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Investing in Sarepta Therapeutics (NASDAQ:SRPT) five years ago would have delivered you a 55% gain - Simply Wall St

Acadian Asset Management LLC Buys New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics appoints new board member - Investing.com

Sarepta Therapeutics appoints new board member By Investing.com - Investing.com Canada

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - citybiz

Sarepta Therapeutics Expands Board, Welcomes New Director - TipRanks

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors - Business Wire

Texas Permanent School Fund Corp Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks - Insider Monkey

Sarepta Therapeutics, Inc. (SRPT): Among Hedge Funds’ Top Biotech Stock Picks - Yahoo Finance

Federated Hermes Inc. Sells 101,887 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 1.5% - MarketBeat

First Turn Management LLC Has $28.70 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

These 2 Biotech Stocks Are Set to Soar - The Motley Fool

Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology - Benzinga

SRPT Makes Notable Cross Below Critical Moving Average - Nasdaq

10 Largest Biotech Hedge Funds and Their Top Stock Picks - Insider Monkey

Natixis Advisors LLC Takes $1.92 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

TD Asset Management Inc Cuts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Advanced Therapy Based on Gene Production Market Segments, - openPR

New Mexico Educational Retirement Board Takes $3.03 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Sarepta Therapeutics, Inc. (SRPT): This Biotech Stock Should Be On Your Radar - Yahoo Finance

Real-World Experience With Duchenne Muscular Dystrophy Gene Therapy - CGTLive™

Unveiling 26 Analyst Insights On Sarepta Therapeutics - Benzinga

Relative Strength Alert For Sarepta Therapeutics - Nasdaq

Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Royal Bank of Canada - MarketBeat

Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report? - Yahoo Finance

Simile a SRPT